Anlai Zou

Sir Run Run Shaw Hospital

Papers

1

Total Citations

22

H-Index

1

About

Anlai Zou is a rising leader in biomedical engineering, whose research converges on the frontier of micro/nanorobotics, inflammatory bowel disease (IBD) therapy, and the gut microbiome. Zou’s most cited work introduces a groundbreaking “Microalgae‐Probiotic‐Nanozyme Robot,” a biohybrid system designed to alleviate intestinal inflammation and correct microbiota dysbiosis. This innovative platform ingeniously combines living microalgae, probiotics, and nanozymes to simultaneously combat oxidative stress, restore gut barrier function, and rebalance microbial communities—addressing key limitations of conventional IBD treatments. Garnering 22 citations since its 2025 publication, this work exemplifies Zou’s ability to integrate synthetic biology, nanotechnology, and robotics for targeted therapeutic delivery. By engineering autonomous, bio-inspired robots that navigate the gastrointestinal tract, Zou is pioneering next-generation strategies for chronic inflammatory conditions. Their research not only offers a paradigm shift in treating IBD but also opens new avenues for intelligent, living therapeutics. For students and researchers, Anlai Zou represents the vanguard of interdisciplinary science—where microalgae, probiotics, and nanozymes unite to create smarter, more effective solutions for complex diseases.

Research Focus

Key Achievements

1
H-Index
1
Papers
22
Total Citations
22
Avg Citations/Paper
🏆 Most Cited Paper
A Microalgae‐Probiotic‐Nanozyme Robot for Alleviating Intestinal Inflammation and Microbiota Dysbiosis
22 citations · 2025
📈 Most Prolific Year: 2025 (1 Papers)
🤝 Key Collaborators: 4
🏛 Institutions: Sir Run Run Shaw Hospital

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago